British Society of Haematology (BSH) guideline on management of relapsed or refractory large B-cell lymphoma

This British Society of Haematology (BSH) guideline outlines the recommended investigation and management of relapsed or refractory large B-cell lymphoma (LBCL). The management of newly diagnosed disease is discussed in a separate guideline. Primary or secondary central nervous system (CNS) lymphoma, primary mediastinal large B-cell lymphoma, mediastinal grey-zone lymphoma and Burkitt lymphoma are outside the scope of this guideline.

The guideline includes a section on patient selection and bridging for CAR T-cell therapy as well as the management of post-CAR T-cell therapy relapse. Therapies in this guideline document may not be licensed or funded in all territories. Clinical trial options are outside the scope of this guideline but should be considered where available. Holistic care with a multidisciplinary approach, including palliative care, should be adopted where appropriate in the management of patients.

The guideline, published on Monday, 19 May 2025, is available at link